Tag: xarelto

Xarelto-obesity

New research reveals decreased risk of recurrent VTE in morbidly obese...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the publication of new real-world evidence which confirms that XARELTO (rivaroxaban) reduces the risk...

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...

FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...

Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...

FDA grants priority review of Xarelto for a 10mg dose to...

The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...

Two new real-world studies confirm positive efficacy and safety profile of...

Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...